ABSTRACT: Two of the most widely measured compounds in the urine of people who use tobacco products are cotinine, a major metabolite of the addictive constituent nicotine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a metabolite of the powerful lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Thousands of analyses have been reported in the literature, carried out exclusively, to the best of our knowledge, by separate methods. In the study reported here, we have developed a sensitive, accurate, and precise liquid chromatography-electrospray ionization-tandem mass spectrometry-selected reaction monitoring method for the combined analysis of total cotinine (the sum of cotinine and its glucuronide) and total NNAL (the sum of NNAL and its glucuronide). The new method quantifies naturally occurring [ 13 C]cotinine to minimize problems associated with the vast differences in concentration of total cotinine and total NNAL in urine. This method should greatly facilitate future determinations of these important compounds.
I n spite of their widely known adverse health effects, tobacco products continue to be a major cause of disease and death, with the average annual smoking-attributable mortality for the United States for 2010−2014 estimated at 500 000 premature deaths, while worldwide the total number of deaths attributable to tobacco use was approximately 6 million.
1,2 It does not seem that the worldwide use of tobacco products will diminish significantly in the near future. Two of the most important compounds in tobacco products are nicotine, its major known addictive constituent responsible in large measure for maintenance of the tobacco habit, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a powerful lung carcinogen in laboratory animals which is widely viewed as one of the most dangerous compounds in tobacco products with respect to lung cancer etiology 3−6 (see structures in Figure 1 ). The uptake of these compounds by people who use tobacco products or are exposed to secondhand smoke has been extensively studied by quantifying two characteristic urinary metabolites: cotinine, a major metabolite of nicotine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a metabolite of NNK ( Figure 1 ). These metabolites occur in urine partially as glucuronide conjugates and are often measured after treatment of the urine with β-glucuronidase, thus giving "total cotinine" and "total NNAL." Total cotinine and total NNAL, which are virtually unique to users of tobacco products and related materials, or people exposed to secondhand tobacco smoke, are excellent indicators of tobacco dose and are directly associated with lung cancer risk in smokers. 7 The literature contains data on total cotinine and total NNAL in urine samples from many thousands of people. 3,6,8−17 Current methodology for quantitation of urinary cotinine and NNAL (free or total) is based almost exclusively on tandem mass spectrometry. As far as we are aware, all studies reported to date, regardless of methodology, have measured urinary cotinine and NNAL separately. 3,6,8−17 The use of separate methods presumably is related in part to the huge difference in concentrations of total cotinine versus total NNAL in urine. Typical average total cotinine concentrations in urine are about 5000−15 000 times greater than those of total NNAL, which can introduce problems associated with dynamic range. In the study reported here, we have solved this problem by analyzing for naturally occurring total [ 13 Urine Samples. The urine samples were obtained from ongoing studies of the University of Minnesota Tobacco Research Programs, approved by the University of Minnesota Institutional Review Board, code number 0908M70881. Two types of urine samples were used in the validation studies. The pooled smokers' urine sample was obtained by combining urine from 8 subjects, each of whom smoked about 20 cigarettes per day, and contributed between 150 and 320 mL from a 24 h urine collection. The pooled smokeless tobacco users' urine sample was obtained by combining 1 mL each of urine samples from 68 subjects who used an average of 3.68 tins of smokeless tobacco per week. Upon validation of the method, urine samples from 85 smokers were used to compare the results for total cotinine and total NNAL from the new combined method to those from previously existing methods.
Combined Analysis of Total Cotinine and Total NNAL in Urine. Urine samples that were previously frozen at −20°C were thawed at 4°C overnight, and 250 μL aliquots were added to 96-well plates. The mixtures in the 96-well plates were transferred onto Isolute SLE+ 96-well plates. A short mild burst of N 2 was used to push the liquid mixture through the frits. The aqueous solution was allowed to absorb onto the diatomaceous earth for 5 min and then eluted 6 times, each with 0.3 mL of CH 2 Cl 2 . After all the eluents were collected through gravity in a True Taper collection plate, the remainder of the material in the Isolute SLE+ 96-well plates was eluted with the aid of a Cerexprocessor and a slow stream of N 2 . The combined eluents were then dried under vacuum in a SpeedVac for 1−1.5 h.
The samples were further purified by a second solid-phase extraction using Oasis MCX 96-well plates. The dried samples were reconstituted in 250 μL of 1 N HCl by sonication for 15 min. The MCX plates were equilibrated with 1 mL of CH 3 OH followed by 2 mL of H 2 O. The reconstituted samples were then added to the MCX plate. The True Taper LC-ESI + -MS/MS was performed with an Ultra triple quadrupole mass spectrometer (Thermo Scientific, Pittsburgh PA) interfaced with a Waters Nano Acquity HPLC system. Chromatographic separation was achieved using a Luna C18 (2) 5 kV, and a capillary temperature of 270°C was used. Typical tube lens offset values were 67 V for cotinine and 60 V for NNAL. N 2 was used as the sheath gas (25 counts). Quantitative analyses were conducted in the SRM mode, with collision energy of 16 V for cotinine and 9 and 17 V for NNAL. Ar was the collision gas with a pressure of 1.1 mTorr. MS/MS analyses were performed using a scan width of m/z 0.2 and a scan time of 0.125 s. Quadrupole resolution was achieved with Q1 set at m/z 0.5 and Q3 set at m/z 0.7.
Accuracy and Precision. Accuracy of the cotinine analysis was determined by spiking a pooled urine sample from 8 smokers, which contained 20.8 nmol total cotinine/mL urine, with cotinine at concentrations of 5.1, 10.1, 20.2, 40.4, or 80.9 nmol/mL urine, and carrying out the analysis. Similarly, a pooled urine sample from 68 smokeless tobacco users containing 21.4 nmol total cotinine/mL urine was spiked with cotinine at concentrations of 5.1, 10.1, 20.2, 40.4, or 80.9 nmol/mL urine. For NNAL, the same urine sample from smokers, which contained 1.8 pmol/mL total NNAL, was spiked with NNAL at concentrations of 0.1, 0.2, 0.4, 0.8, and 1.6 pmol/mL urine while that from smokeless tobacco users, which contained 3.3 pmol/mL total NNAL, was spiked with 2.8, 4.2, 5.6, 8.4, and 14.0 pmol/mL urine.
Precision was determined by replicate analysis of these urine samples with no addition of cotinine or NNAL. Six replicates were carried out for the urine samples from smokers and 3 for + . The cotinine peak in Figure 2A was only 7 times greater in intensity than the NNAL peak in Figure 2B . Chromatograms of similar quality were obtained upon analysis of urine samples from smokeless tobacco users. Limits of quantitation were 0.06 pmol/mL urine for NNAL and 0.42 nmol/mL urine for cotinine.
Accuracy was determined by adding various amounts of cotinine or NNAL to urine samples from smokers and smokeless tobacco users and performing the assay. As illustrated in Figure 3A −D, there was a linear relationship between added and observed amounts. For cotinine, the yintercept was 20.9 nmol/mL in urine samples from smokers ( Figure 3A) , consistent with the 20.8 nmol/mL amount determined in these samples when no cotinine was added. The average accuracy, determined by comparing added and measured amounts at each level of addition, was 99.2%. The corresponding figure for urine samples from smokeless tobacco users ( Figure 3B ) shows a y-intercept of 21.5 nmol/mL versus a level of 21.4 nmol/mL when no cotinine was added and an average accuracy of 98.7%. For total NNAL in smokers' urine, the y-intercept ( Figure 3C ) gave a value of 1.84 pmol/mL compared to an expected value of 1.8 pmol/mL, and the average accuracy was 98.3%; while in the urine from smokeless tobacco users (Figure 3D ), the y-intercept was 3.15 compared to an expected value of 3.3 pmol/mL, and the average accuracy was 98.1%.
Precision was determined by replicate analyses of the urine samples at zero spiked level, 6 replicates from smokers and 3 from smokeless tobacco users, analyzed once per day over 3 days. Intraday and interday precision (coefficient of variation, in %) for cotinine in smokers' urine were 1.2% and 1.1%, respectively, while the corresponding figures in smokeless tobacco users' urine were 0.7% and 0.6%. For total NNAL, intraday and interday precision were 4.4% and 2.7% in smokers' urine and 0.8% and 0.9% in smokeless tobacco users' urine. Average levels of total cotinine and total NNAL in these samples were 20.9 nmol/mL and 1.6 pmol/mL urine, respectively, in smokers' urine and 21.5 nmol/mL and 2.8 pmol/mL, respectively, in smokeless tobacco users' urine.
The new combined method was further validated by comparing the results to those obtained by the traditional separate methods for analysis of total cotinine and total NNAL in urine samples from 85 smokers. The results, which are presented in Figure 4A ,B, show excellent correlation between the data from the traditional and new methods.
The results presented here constitute, to the best of our knowledge, the first report in the literature of a combined method for quantitation of total cotinine and total NNAL in the urine of people who use tobacco products. The method could also be adapted to studies quantifying these metabolites in the urine of nonsmokers exposed to secondhand smoke. Our solution to the problem of a huge dynamic range, which can inhibit quantitation of both of these important compounds, was to decrease the sensitivity of cotinine detection by analysis of naturally occurring [ 13 C]cotinine in the samples. The resulting method has great accuracy and precision and compares favorably to previous separate methods for determination of these important metabolites. This innovative method will facilitate analysis of total cotinine and total NNAL as well as decrease the cost of these analyses by about 30% in future studies of uptake of the important compounds nicotine and NNK in people who use tobacco products. 
